Barclays
BVS icon

Barclays’s Bioventus BVS Stock Holding History

Barclays’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Sell
54,718
-10,077
-16% -$96.2K ﹤0.01% 3206
2026
Q1 		$592K Sell
64,795
-27,728
-30% -$233K ﹤0.01% 3086
2025
Q4 		$688K Buy
92,523
+26,547
+40% +$191K ﹤0.01% 3676
2025
Q3 		$441K Sell
65,976
-22,132
-25% -$154K ﹤0.01% 3890
2025
Q2 		$583K Buy
88,108
+41,032
+87% +$291K ﹤0.01% 3679
2025
Q1 		$431K Sell
47,076
-19,261
-29% -$192K ﹤0.01% 3617
2024
Q4 		$697K Buy
66,337
+15,683
+31% +$185K ﹤0.01% 3623
2024
Q3 		$605K Buy
50,654
+9,854
+24% +$85.2K ﹤0.01% 3657
2024
Q2 		$235K Buy
40,800
+6,498
+19% +$35.6K ﹤0.01% 3495
2024
Q1 		$178K Sell
34,302
-25,290
-42% -$124K ﹤0.01% 4179
2023
Q4 		$314K Buy
59,592
+23,522
+65% +$93.1K ﹤0.01% 4171
2023
Q3 		$119K Buy
+36,070
New +$127K ﹤0.01% 3533
2023
Q2 		– Sell
-18,524
Closed -$19.8K – 4590
2023
Q1 		$19.8K Buy
18,524
+9,945
+116% +$19K ﹤0.01% 4661
2022
Q4 		$22.4K Buy
8,579
+7,239
+540% +$31.6K ﹤0.01% 4783
2022
Q3 		$9K Sell
1,340
-246
-16% -$1.93K ﹤0.01% 4344
2022
Q2 		$11K Sell
1,586
-2,967
-65% -$30.3K ﹤0.01% 4591
2022
Q1 		$65K Sell
4,553
-29,475
-87% -$395K ﹤0.01% 3994
2021
Q4 		$493K Buy
34,028
+27,465
+418% +$390K ﹤0.01% 3210
2021
Q3 		$93K Buy
6,563
+5,510
+523% +$84.8K ﹤0.01% 3932
2021
Q2 		$19K Sell
1,053
-6,509
-86% -$105K ﹤0.01% 4504
2021
Q1 		$116K Buy
+7,562
New +$108K ﹤0.01% 3938

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's BVS Position: Q2 2026 in Review

Barclays reduced its Bioventus (BVS) stake by 16% in Q2 2026, selling an estimated $96.2K and leaving 54,718 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

Barclays first reported a position in BVS in Q1 2021 and has held it in 21 quarters since. The position peaked at $697K in Q4 2024. 156 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Barclays held 54,718 shares of Bioventus worth $517K as of Q2 2026.
  • Barclays sold 10,077 Bioventus shares in Q2 2026, an estimated $96.2K.
  • Bioventus made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3206 holding.
  • Barclays first reported a position in Bioventus in Q1 2021 and has held it in 21 quarters since.
  • Barclays's Bioventus position peaked at $697K in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.